SCHEMBL16600129

SCHEMBL16600129

OB(O)c1cnc(N2CCCCC2)nc1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.52
LIPE Q05469 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 2/20 0.43
ACHE P22303 2/20 0.41
GBA1 P04062 1/20 0.41
CYP11B2 P19099 1/20 0.41
PDE5A O76074 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
PTPN11 Q06124 1/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
NPC1 O15118 1/20 0.38
CASP3 P42574 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2724131 0.77 LIPE (0.51) HRH4LIPEALDH1A1PDE5AL3MBTL1
SCHEMBL2489239 0.76 PIN1 (0.56) HRH4LIPEALDH1A1ACHEPDE5A
SCHEMBL26077214 0.76 KIT (0.53) SMN1; SMN2ALDH1A1TSHRHSD17B10HRH3
SCHEMBL15953346 0.76 KIT (0.53) SMN1; SMN2ALDH1A1TSHRHSD17B10HRH3
SCHEMBL15953075 0.75 HRH4 (0.55) HRH4SMN1; SMN2ALDH1A1ACHEGBA1
SCHEMBL15952657 0.74 KIT (0.54) HRH4SMN1; SMN2ALDH1A1CYP11B2HTT
SCHEMBL2487650 0.74 LIPE (0.48) HRH4LIPESMN1; SMN2ALDH1A1PDE5A
SCHEMBL15952449 0.74 HRH4 (0.56) HRH4SMN1; SMN2ALDH1A1ACHEGBA1
SCHEMBL19240391 0.73 HRH4 (0.66) HRH4ALDH1A1ACHELMNATSHR
SCHEMBL30801285 0.73 ALDH1A1 (0.49) HRH4SMN1; SMN2ALDH1A1ACHEGBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20160280699-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-29 US disclosed
EP-3049403-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2016-08-03 EP disclosed
WO-2015044172-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280699-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES PAH, PEPD, AADAT HRH4 1864/4885LIPE 2164/4885SMN1; SMN2 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.